Clorox Co (CLX) Stock Price Today
Aura AI Summary
Key Stats
- $11.81BMarket Cap
- -Volume
- Consumer StaplesSector
- $127.1652W High
- $86.1252W Low
- -Typical Hold Time
- $17.19BEnterprise Value
- 5.12%Div Yield
- -Trading Activity
Track Clorox Co (CLX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Clorox Co has traded between a low of $86.12 and a high of $127.16, highlighting its annual price range. Buy and sell Clorox Co shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Most Recent News
Tectonic Therapeutic advances TX45 trial with strong data and solid cash runway through 2029, reducing financing risks.
Tectonic Therapeutic has shown promising Phase 1b data for its TX45 drug targeting pulmonary hypertension in heart failure patients, supported by external Merck trial results. The company’s financial position is strong, with cash to fund operations t...
US federal debt tops $40T as massive AI data center investments boost economy and tech growth.
US federal debt has surpassed $40 trillion, driven by significant government and corporate borrowing to fund a large-scale AI data center infrastructure expansion. Despite high debt levels, the economy remains strong with a 4.1% unemployment rate in ...
Dogwood Therapeutics advances Halneuron for chemo-induced neuropathic pain, plans trial for SP16 adjunct therapy.
Dogwood Therapeutics, a clinical-stage biotech company, highlighted progress on Halneuron, a NaV1.7 inhibitor aimed at treating chemotherapy-induced neuropathic pain. The company also announced plans to start clinical trials for SP16, an LRP1 agonist...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.